Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Raynaud

Showing results (81-90 of 92) with videos related to

Pageof 10
Sort By:
European Journal of Biochemistry|December 26, 2001
Binding of gelsolin domain 2 to actin. An actin interface distinct from that of gelsolin domain 1 and from ADF/cofilinC Renoult, L Blondin, A Fattoum, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2000
Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphomaJ S Waters, A Webb, D Cunningham, et al.
British Journal of Cancer|April 3, 2003
A Phase I clinical and pharmacological study of cis-diamminedichloro(2-methylpyridine) platinum II (AMD473)P Beale, I Judson, A O'Donnell, et al.
Biochemical and Biophysical Research Communications|August 31, 1992
Calcitonin gene-related peptide: an autocrine growth factor with regulatory activity in vitroN Segond, P Gerbaud, M Cressent, et al.
British Journal of Cancer|May 20, 2004
Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancerA O'Donnell, I Judson, M Dowsett, et al.
British Journal of Cancer|October 14, 2005
A phase I pharmacokinetic and pharmacodynamic study of BGC9331 and carboplatin in relapsed gynaecological malignanciesT Benepal, A Jackman, L Pyle, et al.
Cancer Chemotherapy and Pharmacology|February 22, 2002
A study of amsalog (CI-921) administered orally on a 5-day schedule, with bioavailability and pharmacokinetically guided dose escalationD Fyfe, F Raynaud, R E Langley, et al.
Marine Biotechnology (New York, N.Y.)|February 13, 2004
Postmortem degradation of white fish skeletal muscle (sea bass, Dicentrarchus labrax): fat diet effects on in situ dystrophin proteolysis during the prerigor stageC Bonnal, F Raynaud, C Astier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1997
Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancerM J McKeage, F Raynaud, J Ward, et al.
BMJ Military Health|April 29, 2022
Vaccine efficacy against the SARS-CoV-2 Delta variant during a COVID-19 outbreak aboard a military shipNancy Maugey, T Lefebvre, J-N Tournier, et al.
Pageof 10

Showing results (81-90 of 92) with videos related to

Sort By:
Pageof 10
European Journal of Biochemistry|December 26, 2001
Binding of gelsolin domain 2 to actin. An actin interface distinct from that of gelsolin domain 1 and from ADF/cofilinC Renoult, L Blondin, A Fattoum, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2000
Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphomaJ S Waters, A Webb, D Cunningham, et al.
British Journal of Cancer|April 3, 2003
A Phase I clinical and pharmacological study of cis-diamminedichloro(2-methylpyridine) platinum II (AMD473)P Beale, I Judson, A O'Donnell, et al.
Biochemical and Biophysical Research Communications|August 31, 1992
Calcitonin gene-related peptide: an autocrine growth factor with regulatory activity in vitroN Segond, P Gerbaud, M Cressent, et al.
British Journal of Cancer|May 20, 2004
Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancerA O'Donnell, I Judson, M Dowsett, et al.
British Journal of Cancer|October 14, 2005
A phase I pharmacokinetic and pharmacodynamic study of BGC9331 and carboplatin in relapsed gynaecological malignanciesT Benepal, A Jackman, L Pyle, et al.
Cancer Chemotherapy and Pharmacology|February 22, 2002
A study of amsalog (CI-921) administered orally on a 5-day schedule, with bioavailability and pharmacokinetically guided dose escalationD Fyfe, F Raynaud, R E Langley, et al.
Marine Biotechnology (New York, N.Y.)|February 13, 2004
Postmortem degradation of white fish skeletal muscle (sea bass, Dicentrarchus labrax): fat diet effects on in situ dystrophin proteolysis during the prerigor stageC Bonnal, F Raynaud, C Astier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1997
Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancerM J McKeage, F Raynaud, J Ward, et al.
BMJ Military Health|April 29, 2022
Vaccine efficacy against the SARS-CoV-2 Delta variant during a COVID-19 outbreak aboard a military shipNancy Maugey, T Lefebvre, J-N Tournier, et al.
Pageof 10